Hossam Kamli^*, Gaffar S. Zaman^*, Ahmad Shaikh^*, Abdullah A. Mobarki^†, Prasanna Rajagopalan^*‡

Oncology Research, Vol.28, No.9, pp. 899-911, 2020, DOI:10.3727/096504021X16281573507558

Abstract Inhibition of the dihydroorotate dehydrogenase (DHODH) has been successful at the preclinical level in controlling myeloid leukemia. However, poor clinical trials warrant the search for new potent DHODH inhibitors. Herein we present a novel DHODH inhibitor SBL-105 effective against myeloid leukemia. Chemical characteristics were identified by ¹ H NMR, ¹³C NMR, and mass spectroscopy. Virtual docking and molecular dynamic simulation analysis were performed using the automated protocol with AutoDock-VINA, GROMACS program. Human-recombinant (rh) DHODH was used for enzyme inhibition study. THP-1, TF-1, HL-60, and SKM-1 cell lines were used. MTT assay was used to assess cell viability. Flow cytometry was… More >

Hui Li^*1, Han-Han Li^†1, Qian Chen^‡1, Yu-Yang Wang^‡, Chang-Chang Fan^‡, Yuan-Yuan Duan^‡, You Huang^‡, Hui-Min Zhang^‡, Jia-Peng Li^‡, Xiao-Yu Zhang^‡, Yuan Xiang^‡, Chao-Jiang Gu^‡, Li Wang^§, Xing-Hua Liao^‡, Tong-Cun Zhang^‡¶

Oncology Research, Vol.28, No.9, pp. 885-897, 2020, DOI:10.3727/096504021X16274672547967

Abstract Abnormal cell proliferation caused by abnormal transcription regulation mechanism seems to be one of the reasons for the progression of breast cancer and also the pathological basis. MicroRNA-142-5p (miR-142-5p) is a low-expressed miRNA in breast cancer. The role of MKL-1’s regulation of DNMT1 in breast cancer cell proliferation and migration is still unclear. MKL-1 (myocardin related transcription factor A) can bind to the conserved cis-regulatory element CC (A/T) 6GG (called CarG box) in the promoter to regulate the transcription of miR-142-5p. The expressions of miR-142-5p and MKL-1 are positively correlated. In addition, it has been proved that DNMT1 is the… More >

Elena Andreucci^*1, Anna Laurenzana^*, Silvia Peppicelli^*, Alessio Biagioni^*, Francesca Margheri^*, Jessica Ruzzolini^*, Francesca Bianchini^*, Gabriella Fibbi^*, Mario Del Rosso^*†, Chiara Nediani^*, Simona Serratì^‡, Livia Fucci^§, Michele Guida^¶, Lido Calorini^*†1

Oncology Research, Vol.28, No.9, pp. 873-884, 2020, DOI:10.3727/096504021X16273798026651

Abstract Malignant melanoma is a highly aggressive skin cancer characterized by an elevated grade of tumor cell plasticity. Such plasticity allows adaptation of melanoma cells to different hostile conditions and guarantees tumor survival and disease progression, including aggressive features such as drug resistance. Indeed, almost 50% of melanoma rapidly develop resistance to the BRAFV600E inhibitor vemurafenib, with fast tumor dissemination, a devastating consequence for patients’ outcomes. Vasculogenic mimicry (VM), the ability of cancer cells to organize themselves in perfused vascular-like channels, might sustain tumor spread by providing vemurafenibresistant cancer cells with supplementary ways to enter into circulation and disseminate. Thus, this… More >

Weili Min^*1, Liangzhang Sun^†1, Burong Li^‡, Xiao Gao^*, Shuqun Zhang^*, Yang Zhao^*

Oncology Research, Vol.28, No.9, pp. 857-872, 2020, DOI:10.3727/096504021X16203818567367

Abstract EMT confers increased metastatic potential and the resistance to chemotherapies to cancer cells. However, the precise mechanisms of EMT-related chemotherapy resistance remain unclear. c-Src-mediated caspase 8 phosphorylation essential for EMT in lung adenocarcinoma cell lines preferentially occurs in cells with the mesenchymal phenotype, resulting in chemoresistance to cisplatin plus paclitaxel in patients with resectable lung adenocarcinoma and a significantly worse 5-year PFS. Cisplatin killed lung adenocarcinoma cells regardless of caspase 8. Paclitaxel-triggered necroptosis in lung adenocarcinoma cells was dependent on the phosphorylation or deficiency of caspase 8, during which FADD interacted with RIPK1 to activate the RIPK1/RIPK3/MLKL signaling axis. Accompanied… More >

Chiara Dalle Fratte^*, Silvia Mezzalira^*, Jerry Polesel^†, Elena De Mattia^*, Antonio Palumbo^‡, Angela Buonadonna^§, Elisa Palazzari^¶, Antonino De Paoli^¶, Claudio Belluco^#, Vincenzo Canzonieri^‡** , Giuseppe Toffoli^*, Erika Cecchin^*

Oncology Research, Vol.28, No.9, pp. 847-855, 2020, DOI:10.3727/096504021X16232280278813

Abstract Pathological complete response after neoadjuvant chemoradiotherapy in locally advanced rectal cancer patients is related to a favorable prognosis. The identification of early biomarkers predictive of pathological complete response would help optimize the multimodality management of the patients. A panel of 11 tumor-related proteins was investigated by immunohistochemistry in the pretreatment biopsy of a group of locally advanced rectal cancer patients to identify early biomarkers of pathological complete response to neoadjuvant chemoradiotherapy. A mono-institutional retrospective cohort of 95 stage II/III locally advanced rectal cancer patients treated with neoadjuvant chemoradiotherapy and surgery was selected based on clinical–pathological characteristics and the availability of… More >

Rosa Della Monica^*1, Mariella Cuomo^*†1, Roberta Visconti^‡, Annabella di Mauro^§, Michela Buonaiuto^*, Davide Costabile^*†, Giulia De Riso^†, Teodolinda Di Risi^*, Elia Guadagno^¶, Roberto Tafuto^#, Sabrina Lamia^**, Alessandro Ottaiano^††, Paolo Cappabianca^#, Maria Laura Del Basso de Caro^¶, Fabiana Tatangelo^§, Juergen Hench^‡‡, Stephan Frank^‡‡, Salvatore Tafuto^**, Lorenzo Chiariotti^*†

Oncology Research, Vol.28, No.9, pp. 837-845, 2020, DOI:10.3727/096504021X16214197880808

Abstract Unresectable neuroendocrine neoplasms (NENs) often poorly respond to standard therapeutic approaches. Alkylating agents, in particular temozolomide, commonly used to treat high-grade brain tumors including glioblastomas, have recently been tested in advanced or metastatic NENs, where they showed promising response rates. In glioblastomas, prediction of response to temozolomide is based on the assessment of the methylation status of the MGMT gene, as its product, O6 -methylguanine-DNA methyltransferase, may counteract the damaging effects of the alkylating agent. However, in NENs, such a biomarker has not been validated yet. Thus, we have investigated MGMT methylation in 42 NENs of different grades and from… More >

Lili Lv^*, Xiaodong Wang^†

Oncology Research, Vol.28, No.7-8, pp. 835-835, 2020

Abstract This article has no abstract. More >

Chao Jiang^*, Xueyan Liu^†, Meng Wang^*, Guoyue Lv^*, Guangyi Wang^*

Oncology Research, Vol.28, No.7-8, pp. 833-833, 2020, DOI:10.3727/096504018X16233193839045

Abstract This article has no abstract. More >

Zhili Cao^*1, Xiang Zheng^†1, Lei Cao^*, Naixin Liang^*

Oncology Research, Vol.28, No.7-8, pp. 831-831, 2020, DOI:10.3727/096504020X16231418632584

Abstract This article has no abstract. More >

Wenliang Liu^*, Peng Xiao^†, Han Wu^*, Li Wang^*, Demiao Kong^*, Fenglei Yu^*

Oncology Research, Vol.28, No.7-8, pp. 829-829, 2020, DOI:10.3727/096504021X16207253542097

Abstract This article has no abstract. More >